PetMed Express (PETS) Earning Somewhat Favorable News Coverage, Study Finds
Media headlines about PetMed Express (NASDAQ:PETS) have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PetMed Express earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6691605885683 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm (finance.yahoo.com)
- Cooper Companies (COO) Tops Q4 Earnings & Revenue Estimates – Nasdaq (nasdaq.com)
- PetMed Express, Inc. (PETS) Expected to Post Earnings of $0.35 Per Share (americanbankingnews.com)
- PetMed Express (PETS) Lifted to Strong-Buy at BidaskClub (americanbankingnews.com)
- PetMed Express Target of Unusually Large Options Trading (PETS) (americanbankingnews.com)
Several research firms recently weighed in on PETS. Craig Hallum reaffirmed a “hold” rating and issued a $40.00 price objective (down from $43.00) on shares of PetMed Express in a research note on Monday, August 21st. They noted that the move was a valuation call. BidaskClub raised PetMed Express from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Sidoti raised PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Thursday, August 24th. ValuEngine raised PetMed Express from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research raised PetMed Express from a “sell” rating to a “hold” rating and set a $50.00 price objective on the stock in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.00.
Shares of PetMed Express (PETS) opened at $43.51 on Wednesday. The firm has a market capitalization of $883.31, a PE ratio of 28.77, a P/E/G ratio of 2.57 and a beta of 1.13. PetMed Express has a 12 month low of $19.21 and a 12 month high of $50.90.
PetMed Express (NASDAQ:PETS) last released its quarterly earnings data on Monday, October 23rd. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.13. PetMed Express had a return on equity of 31.46% and a net margin of 11.58%. The business had revenue of $66.70 million for the quarter, compared to analyst estimates of $63.41 million. During the same period last year, the firm posted $0.24 earnings per share. PetMed Express’s revenue was up 9.7% compared to the same quarter last year. equities research analysts predict that PetMed Express will post 1.67 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, November 17th. Stockholders of record on Monday, November 6th were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.84%. The ex-dividend date was Friday, November 3rd. PetMed Express’s payout ratio is 53.69%.
In other news, Director Ronald J. Korn sold 1,000 shares of PetMed Express stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $35.57, for a total transaction of $35,570.00. Following the sale, the director now directly owns 73,833 shares of the company’s stock, valued at $2,626,239.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “PetMed Express (PETS) Earning Somewhat Favorable News Coverage, Study Finds” was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/petmed-express-pets-earning-somewhat-favorable-news-coverage-study-finds/1760488.html.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with Analyst Ratings Network's FREE daily email newsletter.